# US 2026/0092930 A1 · Desmin tyrosine phosphorylated mutant and pancreatic cancer

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0092930 A1
- Document ID: US20260092930A1
- Status: Published application
- Kind: A1
- Application number: 19/348,598
- Filed: 2025-10-02
- Published: 2026-04-02
- Earliest claimed: 2024-10-02
- Assignees: Kendrick Laboratories, Inc.; Clarkson University
- Applicants: Kendrick Laboratories, Inc.; Clarkson University
- Inventors: Nancy KENDRICK; Jon JOHANSEN; Matt HOELTER; Andrew KOLL; Costel C. DARIE
- Web page: https://patentgrep.com/patent/US20260092930A1

## CPC

- G01N 33/6893: {related to diseases not provided for elsewhere}
- C07K 14/47: from mammals
- C07K 14/4716: {Muscle proteins, e.g. myosin, actin}
- G01N 1/28: Preparing specimens for investigation {including physical details of (bio-)chemical methods covered elsewhere, e.g. G01N33/50, C12Q}(mounting specimens on microscopic slides G02B21/34; means for supporting the objects or the materials to be analysed in electron microscopes H01J37/20 {; laboratory gas handling apparatus B01L5/00})
- G01N 33/6848: {Methods of protein analysis involving mass spectrometry}
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- G01N 2800/06: Gastro-intestinal diseases
- G01N 2800/32: Cardiovascular disorders
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

The present invention provides methods for detecting a mutant desmin protein comprising a phosphorylated D399Y mutation. In some embodiments, the methods are used to diagnose cancer in a subject. Also provided are compositions comprising or constructs encoding a fragment of the mutant desmin protein with a phosphorylated tyrosine residue at position 399 corresponding to a D399Y mutation and methods of using these compositions to treat cancer.

## Claims

### Claim 1

A method for detecting a mutant desmin protein comprising a phosphorylated D399Y mutation, the method comprising:
obtaining a sample from a subject; and
detecting the mutant desmin protein in the sample, wherein the mutant desmin protein comprises a tyrosine residue at position 399 that is phosphorylated.

### Claim 2 (depends on 1)

The method of claim 1, wherein the sample is a pancreatic tissue sample.

### Claim 3 (depends on 1)

The method of claim 1, wherein detecting the mutant desmin protein comprises using mass spectrometry.

### Claim 4 (depends on 1)

The method of claim 1, wherein detecting the mutant desmin protein comprises using an antibody-based detection method.

### Claim 5 (depends on 4)

The method of claim 4, wherein the antibody-based detection method is selected from the group consisting of western blotting, immunohistochemistry, and enzyme-linked immunosorbent assay.

### Claim 6 (depends on 1)

The method of claim 1, further comprising a step of homogenizing the sample in a buffer comprising sodium dodecyl sulfate prior to detecting the mutant desmin protein and optionally further comprising a step of boiling the homogenized sample prior to the detecting step.

### Claim 7 (depends on 1)

The method of claim 1, wherein the detection of the mutant desmin protein comprising a tyrosine residue at position 399 is indicative of a myopathy, optionally a cardiomyopathy.

### Claim 8 (depends on 2)

The method of claim 2, wherein the method is used to diagnose pancreatic ductal adenocarcinoma in the subject.

### Claim 9

A composition comprising a fragment of a mutant desmin protein, wherein the fragment comprises a phosphorylated tyrosine residue at position 399 corresponding to a D399Y mutation in wild-type desmin.

### Claim 10 (depends on 9)

The composition of claim 9, wherein the fragment comprises the amino acid sequence MALYVEIATYR (SEQ ID NO: 3).

### Claim 11 (depends on 9)

The composition of claim 9, wherein the fragment is between 5 and 20 amino acids in length.

### Claim 12 (depends on 9)

The composition of claim 9, further comprising a pharmaceutically acceptable carrier.

### Claim 13 (depends on 12)

The composition of claim 12, wherein the pharmaceutically acceptable carrier is selected from the group consisting of liposomes, nanoparticles, and extracellular vesicles.

### Claim 14 (depends on 13)

The composition of claim 13, wherein the composition is formulated for therapeutic use in treating cancer and the cancer is optionally a pancreatic ductal adenocarcinoma.

### Claim 15 (depends on 9)

A method of treating cancer in a subject, the method comprising:
administering to the subject the composition of claim 9.

### Claim 16 (depends on 15)

The method of claim 15, wherein the cancer is pancreatic ductal adenocarcinoma.

### Claim 17 (depends on 16)

The method of claim 16, wherein the fragment comprises the amino acid sequence MALYVEIATYR.

### Claim 18 (depends on 17)

The method of claim 17, wherein the composition is administered intravenously.

### Claim 19 (depends on 15)

The method of claim 15, wherein the subject has a cancer expressing a mutant desmin protein comprising a phosphorylated D399Y mutation.

### Claim 20

A construct comprising a polynucleotide encoding at least a portion of SEQ ID NO: 6 operably connected to a promoter, wherein the portion of SEQ ID NO: 6 comprises at least 8 amino acids and includes amino acid 399Y.
